Q-omics provides the consensus-scored MIR558 profile across patient tissues and cancer cell-line models. MIR558 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR558 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, MIR558 RNA expression shows 6,492 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight HNSC, STAD, and LAML as cancer lineages where MIR558 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR558 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR558 survival associations across molecular data types. MIR558 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR558 RNA expression–survival associations across cancer types. High MIR558 expression shows unfavorable associations in LIHC, ACC, STAD, KIRC and MESO, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR558 RNA expression.
This table summarizes MIR558 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR558. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR558 shows higher tumor expression in STAD. The STAD box plot shows higher MIR558 RNA expression in tumor versus normal tissue (log2 FC = +0.641, t-test p = .007).
This table shows molecular features associated with MIR558 in patient tissues and cancer cell lines. In patient samples, MIR558 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
